Abstract 562P
Background
Osi is a third-generation, CNS active EGFR-TKI. The primary analysis of the global, phase III, open-label, randomised FLAURA2 (NCT04035486) study in pts with EGFRm advanced NSCLC demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with 1L osi + chemotherapy (osi + CT) vs osi monotherapy (osi-mono). We report data of pts in China from FLAURA2.
Methods
Eligible pts (aged ≥18 yrs with locally advanced/metastatic EGFRm [Ex19del/L858R] NSCLC, WHO PS 0/1 and no prior systemic treatment [tx] for advanced NSCLC; stable CNS metastases allowed) were randomised 1:1 to osi + CT (osi 80 mg QD + pemetrexed [pem] 500 mg/m2 + either cisplatin 75 mg/m2 or carboplatin AUC5 Q3W for 4 cycles, followed by osi 80 mg QD + pem 500 mg/m2 Q3W) or osi-mono (80 mg QD) until progression/discontinuation criterion; stratified by race (Chinese Asian/non-Chinese Asian/non-Asian), EGFR mutation test method (local/central) and WHO PS (0/1). Primary endpoint: PFS by investigator assessment. Secondary endpoints included OS, ORR, DoR and safety. Data cut-off: 03 April 2023.
Results
Overall, 131 pts in China were randomised to osi + CT (n=67) or osi-mono (n=64). Baseline characteristics (osi + CT/osi-mono) were: median age (range), 61 (42–74)/60 (32–78) yrs; 63/59% female; 48/59% Ex19del; 51/39% L858R (1 unknown EGFR mutation type per arm); 51/42% CNS metastases. Osi + CT improved PFS vs osi-mono (49% maturity by investigator; Table). OS was immature (21% maturity); HR 0.97 (95% CI 0.45, 2.06). All grade ≥3 AEs (osi + CT/osi-mono): 75% (mainly haematological)/26%; AEs leading to osi discontinuation: 3/5%.
Conclusions
In the China cohort, osi + CT demonstrated a clinically meaningful improvement in PFS over osi-mono with a manageable safety/tolerability profile consistent with the global study population, supporting osi + platinum-pem as a new 1L tx option for pts in China with advanced EGFRm NSCLC. Table: 562P
Efficacy output | Osi + CT (n=67) | Osi-mono (n=64) |
Median PFS by investigator, months (95% CI) | 27.4 (22.3, NC) | 22.3 (16.7, 25.0) |
HR (95% CI) | 0.56 (0.34, 0.92) | |
Median follow-up for PFS, months (range)* | 22.3 (0–30.6) | 23.7 (3.0–33.1) |
Median PFS by BICR, months (95% CI) | 33.2 (25.1, NC) | 22.0 (16.6, NC) |
HR (95% CI) | 0.58 (0.34, 1.01) | |
Median follow-up for PFS, months (range)* | 24.2 (0–30.5) | 22.3 (3.0–33.2) |
ORR by investigator, n (%) | 58 (87) | 49 (77) |
Median DoR by investigator, months (95% CI) | 26.2 (20.7, NC) | 20.8 (15.3, 23.5) |
∗In censored pts.BICR, blinded independent central review; CI, confidence interval; DoR, duration of response; HR, hazard ratio; NC, not calculable; NR, not reached; ORR, objective response rate
Clinical trial identification
FLAURA2: NCT04035486.
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, Ph.D., of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
L. Jiang: Non-Financial Interests, Personal, Local PI: Shanghai Chest Hospital, Shanghai Jiao Tong University, PR China. J. Liu, Y. Liu: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. D. Kulkarni, X. Huang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. P.A. Jänne: Financial Interests, Personal, Advisory Board: AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyte, Takeda Oncology, Novartis, Voronoi, SFJ Pharmaceuticals, Biocartis, LOXO Oncology, PUMA, Sanofi, Transcenta, Daiichi Sa; Financial Interests, Personal, Other: Dr. Jänne is a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Oncology, PUMA, Astellas Pharmaceuticals, Daiichi Sankyo; Financial Interests, Personal, Royalties: Post marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp. All other authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract